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Rhod-2l role in intracellular Ca2+ signalling by taking up and releasing the ion upon
speciﬁc conditions. In order to do so, mitochondria depend on a number of factors, such as the mitochondrial
membrane potential and spatio-temporal constraints. Whereas most of the basic principles underlying
mitochondrial Ca2+ handling have been successfully deciphered over the last 50 years using assays based on
in vitro preparations of mitochondria or cultured cells, we have only just started to understand the actual
physiological relevance of these processes in the whole animal. Recent advancements in imaging and
genetically encoded sensor technologies have allowed us to visualise mitochondrial Ca2+ transients in live
mice. These studies used either two-photon microscopy or bioluminescence imaging of cameleon or
aequorin-GFP Ca2+ sensors, respectively. Both methods revealed a consistent picture of Ca2+ uptake into
mitochondria under physiological conditions even during very short-lasting elevations of cytosolic Ca2+
levels. The big future challenge is to understand the functional impact of such Ca2+ signals on the physiology
of the observed tissue as well as of the whole organism. To that end, the development of multiparametric in
vivo approaches will be mandatory.
© 2008 Elsevier B.V. All rights reserved.1. Functional roles of Ca2+ in mitochondriaAccording to the endosymbiont hypothesis mitochondria are
derived from some form of prokaryotes which were eventually
taken up by the ancestors of eukaryotic cells [for reviews, see 1,2].
Instead of being digested, the engulfed organisms apparently
managed to start a very successful mutual interaction with their
hosts. To date, many important cellular functions of mitochondria
have been deciphered, one of which being its role in the handling of
Ca2+ ions [for review, see 3]. As described in detail elsewhere, in many
eukaryotic cell types mitochondria play distinct roles in the Ca2+
game [for review, see 4,5], such as i) they can transiently accumulate
large amounts of Ca2+ as a consequence of cytosolic Ca2+ increases,
thus shaping the kinetics and amplitude of the Ca2+ signal, and ii)
they can modulate the activity of Ca2+ channels by local buffering of
Ca2+ inﬂux through the plasma membrane or intracellular Ca2+
channels. Furthermore, Ca2+ itself may also modulate important
processes inside mitochondria, such as energy metabolism [for
review, see 6,7], hormone metabolism [for review, see 8], or the
release of apoptotic factors [for review, see 9]. Thus, on the one hand,
Ca2+ is managed by mitochondria which affects its cytosolic levels
but, on the other hand, the ion also actively inﬂuences themetabolism
of the organelle. An intriguing feature of mitochondrial Ca2+ handling
is its interaction with the endomembrane system, mainly with the+49 7247 823354.
).
ll rights reserved.endoplasmic reticulum [for review, see 7,10]. This strategic cross-
connection of two major endomembrane network systems would be
ideally suited to control many vital cellular functions. Through the
levels of cytosolic Ca2+ as well as the stimulation of ER-Ca2+ release
by a range of external cues, mitochondria are hooked to the outside
world and thus act as important homeostatic sensors of the cellular
environment [for review, see 8]. Mitochondrial Ca2+ handling has
been extensively studied by different approaches, ranging from
mitochondrial suspensions (in vitro), cell culture, tissue slices (in
situ), and live animals (in vivo). Although most of the mechanisms
concerning mitochondrial Ca2+ handling have been elucidated in vitro
or in cultured cells, we still know very little about the actual
physiological role of these processes in the context of the whole
organism. This is mainly due to technical limitations, but recent sensor
developments have provided new insights into mitochondrial Ca2+
signalling under highly physiological conditions in vivo. This contribu-
tion aims at summarizing the results obtained in the last few years
regarding in vivomeasurement of mitochondrial Ca2+ handling, a ﬁeld
that is still in its infancy. Readers interested in in vitro mitochondrial
Ca2+ homeostasis are referred to other contributions in this special
issue for detailed discussions of the vast literature available.
In the following paragraphs, we will ﬁrst try to outline the major
considerations of when and where in vivomeasurement of mitochon-
drial Ca2+ handling is the most desirable approach. We will then
analyze the current challenges in these in vivo studies. We will
conclude with an overview of possible solutions to overcome at least
some of the present technical limitations.
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2.1. Mitochondrial membrane potential
Initial observations of Ca2+ transport conducted in vitro using
isolated mitochondria were already made in the 1960s and 1970s [for
review, see 5]. At that time, mitochondrial Ca2+ uptake and release
were perceived as active and passive processes, respectively. The
chemiosmotic hypothesis allowed a better clariﬁcation of these vague
concepts and, at present, the uptake of Ca2+ into mitochondria is
understood as an electrogenic process mediated by the ruthenium
red-sensitive mitochondrial Ca2+ uniporter (MCU), with the mito-
chondrial membrane potential acting as the driving force for Ca2+
accumulation into thematrix [for reviews, see 11,12]. This concept was
recently reinforced by the electrophysiological characterisation of
mitoplasts showing high Ca2+ currents that occur across the inwardly
rectifying MCU in the presence of physiologically relevant values of
membrane potential [13]. Under physiological conditions, the rate
limiting step in mitochondrial Ca2+ accumulation is the Ca2+
concentration to which the organelle is exposed (i.e., most often the
local Ca2+ concentration). It is still unclear whether and to what
extent physiological changes in membrane potential can affect the
rate of mitochondrial Ca2+ uptake.
Regarding Ca2+ efﬂux from mitochondria, there is now a general
consensus that this process is mediated by Na+(H+)/Ca2+ antipor-
ters, with the driving force being the ion gradients across the inner
mitochondrial membrane. Given that the antiporters are electrogenic
(they exchange 3 Na+(H+) for 1 Ca2+), their function is also affected
by membrane potential [for review, see 12]. A number of other
parameters may also be of importance for the efﬁcient transport of Ca2
+ into and out of mitochondria. As far as these are relevant for our
considerations of in vivomeasurements, they will be addressed below.
2.2. Space, time and amplitude
Apart from the mitochondrial inner membrane potential, the
quantity and the speed of Ca2+ taken up into mitochondria mostly
depends on the amount of this ion present at mitochondrial Ca2+
uptake sites and the duration of such events. Since Ca2+ levels are
typically highest in close proximity to Ca2+ channels, the spatial
distance of MCUs from these spots is of crucial relevance for the
uptake of the ion into the matrix. In fact, whereas most text books
traditionally depict mitochondria as dot- or worm-like structures
distributed all over the cytoplasm in a seemingly random fashion,
these organelles are now increasingly understood as being highly
interactive, maintaining intense mutual signalling and metabolite
exchange with the rest of the cell. Regarding Ca2+ signals, the ER
seems to be the prime interaction partner [for review, see 10]. A
wealth of literature has demonstrated tight morphological and
functional links between ER-Ca2+ exit and putative mitochondrial
Ca2+ uptake sites [e.g. 14,15] [for reviews, see 7,10]. Furthermore,
although randomly distributed mitochondrial networks are com-
monly found in many tissue culture cells, this is only rarely the case in
the organism. Indeed, mitochondrial networks in situ mostly exhibit
striking localisation patterns, which reﬂect their physiological roles in
a given tissue. Examples for such speciﬁc patterns are (i) mitochon-
drial perigranular localisation in pancreatic acinar cells [16,17], (ii)
enrichment at vesicle release sites of adrenal chromafﬁn cells [18], and
(iii) striated localisation in skeletal and cardiac muscle ﬁbres [for
review, see 19]. Such speciﬁc subcellular distribution is apparently
further enhanced by the occurrence of distinct mitochondrial
microdomains, wherein the matrix Ca2+ content may vary by orders
of magnitude [18]. For some of these cases, strong evidence has been
provided suggesting that the microdomains play pivotal roles in
shaping Ca2+ signals whichmight be important for synaptic plasticity,
transcriptional regulation, exocytic processes, muscle tissue contrac-tility, or tunnelling of Ca2+ transients from one cell pole to the other,
to name just a few [for reviews, see 8,17,20]. In other words, apart from
mitochondrial integrity and membrane potential, also the spatial
arrangement of different organelles towards mitochondria as well as
tissue-speciﬁc mitochondrial localisation patterns are critical for a
proper understanding of this organelle function.
Besides spatial separation, the duration and frequency of Ca2+
transients is key to the transformation of external cues into
intracellular responses. Mitochondria have been shown to participate
in both the shaping of Ca2+ transient kinetics as well as the
transformation of these signals into matching outputs. Mitochondria
may shape Ca2+ signals by different means, including propagation of
Ca2+ waves, induction of oscillations, and sustained release of Ca2+ in
synapses upon intense stimulation [for review, see 20]. A prime
functional output of mitochondria in response to Ca2+ transients lies
in the adaptation of energy metabolism to the cellular demand [for
review, see 6]. Again, these functions depend on a number of systemic
parameters, which are hard to predict in a bottom-up approach that is
just based on the molecular understanding of mitochondria.
Finally, the amplitude of Ca2+ transients might considerably
change depending on experimental conditions. In cell culture
approaches, often supramaximal stimuli leading to large and long-
lasting elevation of cytosolic Ca2+ levels are used to show the
principal existence of a certain postulated uptake mechanism [e.g.
14,16,21–23]. However, rises in cytosolic Ca2+ occurring under
physiological conditions may be often highly localised and limited in
amplitude, such as mitochondrial Ca2+ marks in striated muscle [24],
and cytosolic Ca2+ sparks in neurons and muscle [for review, see 25]
which might eventually trigger a full-blown global Ca2+ transient by
calcium-induced–calcium release (CICR) mechanisms.
2.3. Metabolic aspects and external cues
Mitochondrial Ca2+ uptake is driven by the large mitochondrial
inner membrane potential which either arises from respiration or
from ATP consumption. A corollary is that the robustness of Ca2+
uptake, as well as the interpretation of physiological consequences of
such uptake, critically depends on the metabolic activity and route
(anaerobic/oxidative) of a given experimental system. Interestingly,
in a number of cancer cell lines (including the frequently studied HeLa
cells) anaerobic metabolism prevails over oxidative, while the
situation might be considerably different in many primary cell lines,
intact tissues and organisms [26].
Finally, although mitochondria are located inside cells, ensheathed
by two membranes, apparently lacking any direct contact to the cell
surface, these organelles are far from being buried in the cell; indeed,
they are known to be, for example, prime sensors and actuators of
blood glucose and oxygen levels in the pancreas, the hypothalamus
and the carotid arteries [for review, see 8]. By different means,
including a rise of the cellular ATP/ADP.Pi ratio or of the cytosolic Ca2+
level, mitochondria then modulate in their sensing tissues the
appropriate release of insulin or catecholamines.
3. In vivo measurements
So far, measurements of mitochondrial Ca2+ uptake and release, as
well as the role(s) of these ion ﬂuxes on cellular and tissue
homeostasis, have been almost exclusively investigated in biochem-
ical assays or using tissue culture cells. Collectively, these studies have
undoubtedly led to a broad understanding of the basic mechanisms
underlying Ca2+ handling by mitochondria. Unavoidably, they have
also triggered a plethora of questions concerning their actual
physiological relevance in the live organism. Critical factors like the
amplitude and the spatio-temporal arrangement of Ca2+ transients,
the orientation and organisation of mitochondrial networks and their
interacting organelles, the metabolic activity of a given tissue of
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can hardly be mimicked in vitro. Thus, wherever these features might
play any signiﬁcant role, it is highly desirable to carry out all
measurements in situ and in vivo. At present, a series of probes allows
for the direct monitoring of Ca2+ ﬂuxes into and out of mitochondria,
but their application to in vivo studies is still quite limited. In the
following, we will brieﬂy introduce these currently available probes
and discuss their advantages and draw-backs.
3.1. Chemical probes
As discussed above, energised mitochondria are endowed with a
highly negative membrane potential across the inner membrane,
enabling the accumulation of cationic dyes, such as tetramethylrho-
damine, which is frequently used as marker for mitochondrial
localisation and potential. A Ca2+-dependent derivative, rhod-2 [27],
was introduced in the mid-nineties as a selective mitochondrial Ca2+
sensor [28,29]. Although targeting of rhod-2 into mitochondria has
been shown to be problematic in a some cases (see below), it has
been used in a number of studies investigating mitochondrial Ca2+
handling of cultured cells and slice preparations. The KD for Ca2+ of
this probe, which is now commercially available from a couple of
sources, was found to be 570 nM in vitro, while calibrations in live
cells usually revealed slightly higher values, a phenomenon that is
often observed for calcium sensors in a biological environment. As
in the case of other chemical probes, rhod-2 is mainly used in its
cell-permeant acetoxymethyl (AM) ester. Unlike other probes, the
delocalised positive charge present in rhod-2's AM moiety allows
the accumulation of this dye within the mitochondrial matrix,
where it is hydrolysed and trapped [30]. This property, allied to its
spectral characteristics (excitation and emission in the green-red
part of the visible spectrum make it less susceptible to cellular
autoﬂuorescence), have made rhod-2 the ﬂuorescent Ca2+ indicator
of choice amongst the currently available chemical dyes to study
mitochondrial Ca2+ handling. However, compared to other Ca2+
sensors such as the ratiometric dyes fura-2 or indo-1, rhod-2
responds to increasing Ca2+ levels not by a change in the emission
and/or excitation spectrum, but by a rise in ﬂuorescence emission;
i.e., rhod-2 is an intensity-based Ca2+ sensor. This is one of its major
drawbacks for measurements in live tissue, since there is no
compensation for movement artefacts. Another serious issue
concerns uneven distribution of the dye within mitochondria [31],
which could lead to over- or underestimation of the Ca2+ content in
some regions.
Furthermore, targeting efﬁciency is often problematic with rhod
dyes. While rhod-2 was reported to show reasonably good mitochon-
drial localisation in a number of preparations, such as striated muscle
cells [24,32–53], glial [54–61], neuronal [59,62–77], or acinar cell
cultures [78–84], in other cases important quantities of the probe
were detected in the cytosol, in non-speciﬁc accumulations or
extramitochondrial localisations [85]. In perfused rabbit heart, rhod-
2 was actually found to be completely cytosolic [86–88]. The overt
discrepancies in probe distribution in different experimental systems
may be at least partially explained by the uptake mode of the dye into
cells and mitochondria: since rhod-2 as such is membrane imper-
meant, rhod-2 AM is used for loading. Once inside the cell, the ester is
cleaved, leaving the charged rhod-2 compound trapped intracellu-
larly. However, rhod-2 AM has to penetrate also the mitochondrial
membranes before being hydrolysed and it is likely that removal of
only one of the four AM groups is sufﬁcient to prevent the
accumulation of the dye into the matrix; thus, tissue-dependent
differential activity of cytosolic esterases may at least in part explain
the variable efﬁcacy of mitochondrial accumulation in different
tissues. This hypothesis is corroborated by the observation that
loading of rhod-2 AM at low temperatures – and thus at low esterase
activity – is beneﬁcial for the targeting efﬁciency of the dye [32,89].Evidently, such protocols are hardly applicable in many living
organisms, in particular in homeothermic animals.
Additional problems that, to our knowledge, have not been
addressed until now concern the Ca2+ buffering capacity and the
potential toxicity of the AM hydrolysis. As to the ﬁrst, usually
investigators tend to choose brighter cells for imaging; this also
means that the selected cells bear elevated concentrations of a high
afﬁnity Ca2+ chelator, and are therefore kept under conditions where
mitochondrial Ca2+ buffering may be severely increased. As to the
second, it has to be stressed that, as for all other AM esters, the
hydrolysis products are acetate and formaldehyde, and, to our
knowledge, no systematic investigation of the potentially harmful
effects of these compounds on mitochondrial functions has been
carried out.
A more general limitation of any chemical dye with respect to its
use in vivo is its supply to the tissue of interest. Whereas genetically
encoded probes can be delivered by standard transgenetic approaches
(see below), chemical probes have to be applied in any case either
directly to the tissue or systemically, e.g., via the blood stream.
Although this might pose severe problems in a number tissues, recent
technological advancements, such as the multi-cell bolus loading
technique [90,91], now allow a series of cellular parameters to be
studied in situ and in vivo using chemical sensors.
3.2. Genetically encoded probes
A major advantage of genetically encoded over chemical Ca2+
sensors is that they can be efﬁciently targeted into subcellular
compartments, such as the endoplasmic reticulum, the nucleus or
mitochondria. For this purpose, an arsenal of targeting sequences is
now available to guide proteins according to the signal hypothesis
[92,93] into various speciﬁc localisations within cells. In the case of
mitochondrial probes, mostly short N-terminal peptides from the
yeast cytochrome c oxidase (COX) subunit IV (12 amino acids) or the
human COX subunit VIII (36 amino acids, used in all in vivo studies so
far) were cloned in front of the actual sensor coding sequence.
Notably, both, sensor activity as well as targeting efﬁciency were
found to vary according to the used peptide sequence. Furthermore,
targeting efﬁciency appears to inversely correlate with sensor
complexity. Finally, a systematic analysis of these factors using
distinct GFP-based Ca2+ sensors targeted with different sequences
into mitochondria [94] revealed that the use of duplicated N-terminal
targeting sequences can strongly increase targeting efﬁciency. As to
aequorin, its targeting to the mitochondrial matrix is highly efﬁcient
with a single COX VIII targeting sequence and there is no need to
change this import peptide. In any case, efﬁciency of targeting needs
to be properly veriﬁed, in particular for GFP-based probes, for any new
experimental setup.
3.2.1. Aequorin
Together with GFP, the photoprotein aequorin is responsible for
the green bioluminescent touch response of the marine hydrozoan
jellyﬁsh, Aequorea victoria [95]. While GFP plays the role of a
bioluminescence resonance energy transfer (BRET) acceptor in this
response, aequorin plays the role of donor and delivers the energy
necessary to trigger the BRET reaction [96]. It does so by peroxidizing
(and thus consuming) an aromatic substrate, coelenterazine, upon
activation by calcium ions [for review, see 97]. In the absence of the
GFP acceptor molecule, the aequorin-coelenterazine reaction releases
blue light in a stoichiometrically calcium-dependent manner. This
phenomenon was exploited soon after its discovery in 1962 with
scientists using biochemically isolated aequorin to measure intracel-
lular Ca2+ transients [98,99]. With the publication of the aequorin
sequence in 1985 [100], Ca2+ measurements in live cells using
genetically encoded aequorin became an important tool for the
understanding of cytosolic calcium handling. Regarding the concept of
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with respect to the importance of mitochondria in this phenomenon,
targeting of aequorin into these organelles was a major step forward
[14,101]. In fact, this and a number of following investigations using
mitochondrial aequorin, led to a revival of mitochondria as key players
in the Ca2+ game, showing their tight interactionwith the ER network
and many of the physiological functions now well-known to the
community [for review, see 10].
For a number of reasons, aequorin could be an almost ideal
sensor for mitochondrial calcium measurements in live organisms.
First, it can be genetically expressed and can therefore be
introduced into model organisms such as Drosophila or mouse by
standard transgenic methods [102,103]. Second, aequorin efﬁciently
folds in most cell types into a fully functional protein. Third, using
appropriate targeting sequences, aequorin can be efﬁciently
directed into virtually any speciﬁc location inside the cell [for
review, see 104]. Fourth, aequorin can be genetically modiﬁed,
yielding mutants that allow us to measure Ca2+ from the
submicromolar to the millimolar range of concentrations [18].
Fifth, aequorin consumes its substrate in a stoichiometric and
almost irreversible manner; aequorin-based light production is
therefore highly quantitative [105]. Sixth, aequorin actively pro-
duces light upon binding of calcium; therefore, no excitation light
producing severe background signals in whole animal imaging
approaches is needed [102,103]. Finally, aequorins can be coupled
by genetic means to appropriate BRET acceptor molecules, such as
GFP, thereby permitting the construction and simultaneous usage
of differently targeted sensors or tuning the emission wavelength
for higher tissue penetration efﬁciency [106,107]. A limitation of
the aequorin approach is the low amount of Ca2+-dependent light
production, which can be particularly challenging upon targeting of
the sensor into subcellular compartments [108]. Therefore,
aequorin measurements usually employ cell population analyses
with relatively low spatio-temporal resolution.
Recently, Rogers et al. have described the ﬁrst aequorin-based in
vivo monitoring of mitochondrial Ca2+ handling [103]. These
authors show the generation of a conditional knock-in mouse line
ubiquitously expressing a mitochondrially targeted GFP-aequorin
(mtGA) fusion protein. In this mtGA sensor, the aequorin moiety
acts as Ca2+ sensor, which delivers emission energy to the GFP
acceptor molecule in a BRET process similar to the one observed in
the Aequorea medusae. Although BRET leads to a partial loss of
emission energy, addition of the GFP moiety is beneﬁcial, because it
emits longer wavelength light with higher tissue penetration depth
than the aequorin alone would do. The mtGA could be shown to be
nicely localised in the mitochondrial compartment [103]. Upon
systemic application of coelenterazine, mitochondrial Ca2+ signal-
ling could be reliably studied in different tissues using a biolumi-
nescence imaging device over several hours. This ﬁnding came as a
positive surprise, since coelenterazine (in this case applied systemi-
cally to the animal) is known to be consumed immediately upon
interaction with aequorin and Ca2+. Using nerve-stimulation of
hindlimb muscles in anaesthetised animals the authors demon-
strated the uptake of Ca2+ into mitochondria during single twitch
and tetanic contractions, thereby conﬁrming a precedent in vivo
study employing a mitochondrial cameleon (2mtYC2, see below).
While the spatio-temporal resolution of the 2mtYC2 measurements
were superior to the ones obtained with mtGA, the latter approach
proﬁted from being completely non-invasive, allowing also the
observation of Ca2+ signals in the live, unrestrained and non-
anaesthetised animal. This delivered insights into the development-
dependent formation of whole body mitochondrial calcium wave
patterns. Future studies employing tissue-selective expression
patterns of mtGA in combination with appropriate physiological
questions promise to provide important new data regarding the role
of mitochondrial calcium signalling in physiology.3.2.2. GFP-based Ca2+ sensors
GFP, as well as its spectral mutants and functionally similar
ﬂuorescent proteins (XFPs) from other cnidarian species, have
revolutionised cell biological research. Although described already
in 1962 as a side product of the aequorin puriﬁcation protocol [95],
GFP became a major focus of biological research only more than
30 years later upon the publication of its DNA sequence [109] and the
proof of its heterologous expression in C. elegans [110] and
mammalian cells [111]. Apart from its early employment as gene
reporter or protein localisation tool, XFPswere soon developed further
to be usable as bona ﬁde measuring instruments. In particular, Roger
Tsien, Atsushi Miyawaki and colleagues have been quite successful in
this ﬁeld, setting up custom-made, modular tools that allow to
monitor dynamic changes of intracellular parameters by changes in
the ﬂuorescent properties of modiﬁed XFPs [for review, see 112].
Typically, such probes consist of a sensing ﬂuorescence modulator
domain (e.g., calmodulin and its binding peptide in the Ca2+-sensing
cameleon probes) and one or more XFPs. Upon binding of the cellular
factor which is under investigation (e.g., Ca2+) the sensor-modulator
domain changes its conformation and inﬂuences the ﬂuorescence of
the XFP(s). Currently, two major groups of probes employ inducible
changes either in ﬂuorescence intensity (and/or excitation spectrum)
or in FRET (Förster resonance energy transfer). Well known examples
for the ﬁrst group are camgaroo, pericams [113], pHﬂuorins [114] and
mtAlpHi [115]. Widely used exponents of the second group are
cameleons [116,117], cAMP and cGMP probes [118–121], and enzyme
activity probes [122–125]. Like aequorin, also XFP-based sensors can
be easily targeted into virtually any kind of subcellular compartment
by means of appropriate targeting sequences, although targeting
efﬁciency needs to be controlled properly and sometimes necessitates
tuning [94]. Currently, different XFP-based sensors are employed for
in vitro and – more importantly for the topic of this review – in vivo
visualisation of Ca2+ dynamics. Henceforth these will be termed FCIPs
(ﬂuorescent Ca2+ indicator proteins) and include, to date, FIP-CBSM
[126], camgaroo [127], pericam [127], GCaMP [128] and, in particular,
cameleons [116]. Originally, most of these probes were designed using
the calmodulin-M13 peptide (the 25-residue long calmodulin binding
peptide of myosin light chain kinase) pair as Ca2+-dependent
modulator of XFP ﬂuorescence. Since calmodulin is an abundant
signallingmolecule in many cell types, interference between the FCIPs
and endogenous calmodulin could not be excluded. Nonetheless,
these sensors worked rather well in many different tissue culture
approaches, in C. elegans [129–137], and the fruit ﬂy [138–150] upon
stable expression.
In vertebrates in vivo, stably expressed FCIPs, particularly ﬁrst
generation yellow cameleons, showed weak performance and the
FRET responses upon Ca2+ transients were severely dampened
[151,152]. This led to the exploration of inducible or transient FCIPs
expression in mammals [153–155] as well as of different molecular
designs of FCIPs. Themost prominent examples of suchmodiﬁed FCIPs
include high dynamic range cameleons (YC6.1, with CaM-dependent
kinase kinase sandwiched between the N- and C-termini of calmo-
dulin) [156], cameleons with re-engineered calmodulin and M13
peptide [117,157,158], and cameleon-like Ca2+ sensors based on
troponin C as ‘Ca2+ nose’ [128,159]. Altogether, these different
approaches led to a number of insights mainly into cytosolic Ca2+
handling in brain [for recent reviews, see 160,161].
The literature on organellar Ca2+ handling in live vertebrate tissue
using FCIPs is up to now much more limited [154,155]. Both studies
employed in vivo electro-transfer of cDNAs encoding different
cameleon FCIPs into hindlimb muscles, leading to consistent sensor
expression for at least three weeks upon transfection. Ca2+ transients
in the cytosol [154], in mitochondria [154] or in the sarcoplasmic
reticulum [155] were measured upon application of different skeletal
muscle contraction regimes using two-photon in vivo microscopy.
These investigations ﬁrst showed that also FCIPs containing the
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vertebrate tissue, at least in transient transfections. Second, they
demonstrated the high capability of the ratiometric cameleon FCIPs to
correct even for the comparably strong movement artefacts, which
naturally occur during muscle contraction. With respect to mitochon-
dria in vertebrate muscle, regular uptake of Ca2+ into these organelles
during single twitches as well as upon tetanic stimulation was
demonstrated for the ﬁrst time under highly physiological conditions
and in vivo [154] in a fast-twitch tibialis anterior muscle. Given that
very similar results were recently obtained also in vivo with the
aequorin-based sensor mtGA [103], Ca2+ uptake into vertebrate
muscle mitochondria appears to be a basic and robust feature. It is
therefore tempting to speculate that vertebrate muscle actually uses
this activity-dependent uptake for the adaptation of the mitochon-
drial energy metabolism to the muscle contraction-driven ATP-
demand, as suggested also for other tissue types [for review, see 8].
Direct comparison of the data employing mitochondrial GFP-
aequorin (mtGA) [103] or cameleon (2mtYC2) [154] (Fig. 1, schematic
of experimental setups) reveals further similarities. First, in both cases
intense tetanic stimulation led to mitochondrial Ca2+ elevations that
persisted for a couple of seconds longer than the actual duration of the
stimulus, suggesting a transient storage function of the organelle at
high Ca2+ loads. Second, upon single twitches, the Ca2+ transients
were apparently much shorter, with a completion time in the
millisecond range. Pharmacologic interferencewith themitochondrial
Na+/Ca2+ exchanger slowed down the Ca2+ decay, suggesting that
this was actually due to active expulsion of Ca2+ from mitochondria
rather than due to Ca2+ precipitation or other mechanisms [154].
Finally, a clear positive correlation between muscle activity and the
dimension of mitochondrial Ca2+ was observed [103]. Both, the mtGA
and the 2mtYC2 approaches display advantages and disadvantages,
which are largely complementary. While themtGAmeasurements canFig. 1. Schematic of the experimental setups currently used to measure mitochondrial Ca2+
expressing animal is placed under a luminescence imager equipped with a high-sensitivi
transient rise of mitochondrial Ca2+ levels, bioluminescence light is emitted from the coele
behaving animal. Right picture: FRET imaging approach; the anaesthetised, 2mtYC2 cam
equipped with a high resolution water immersion objective. Upon excitation of Cyan Fluores
(YFP) emission signals of the cameleon sensor are detected simultaneously by photom
mitochondrial Ca2+ levels leads to a change in FRET, measurable by a variation in the YFP-to
and FRET imaging methods.be carried out in a completely non-invasive manner and thus also on
behaving animals, ﬂuorescence microscopy usually asks for sterical
ﬁxation of the object of interest, unless particular, sophisticated
methods such as implanted miniature microscopes [162] are used. A
further advantage of the mtGA approach is its wide ﬁeld of
observation, i.e., a whole animal can be surveyed, in contrast to
ﬂuorescence microscopy, which will be limited to an optical ﬁeld of at
most few squaremillimetres. Again, new imaging technologies such as
selective plane illumination microscopy (SPIM) might, in future,
overcome this limitation of ﬂuorescence microscopy [163]. As a
bioluminescence approach, mtGA can also be advantageous, because
it deals with virtually zero background noise, whereas any type of
ﬂuorescence microscopy has to cope with signals originating from
sources other than the sensor itself, which deteriorates its signal-to-
noise ratio. However, aequorin bioluminescence also comes at the
expense of comparably low photon yield, leading to an important
trade-off between image acquisition speed and spatial resolution.
As such, ﬂuorescence microscopy is usually much faster than
bioluminescence measurements and it exhibits signiﬁcantly better
spatial resolution. In conclusion, the mtGA- and 2mtYC2-based
approaches appear to be pretty complementary raising big hopes
for future research addressing mitochondrial Ca2+ handling in live
animals.
4. Future challenges
At the time of writing, the aequorin-based bioluminescence and
the cameleon-based ﬂuorescence approaches seem to hold most
promises for a reliable monitoring of mitochondrial Ca2+ handling in
live animals. We are still far from a satisfying tool set, though. First of
all, both assay systems exhibit severe inherent limitations (see above),
whichmight be partially solved by future technological achievements,signalling in vivo. Left picture: BRET imaging approach; the anaesthetised, stably mtGA
ty CCD camera. During nerve-electrode evoked muscle contraction, which leads to a
nterazine-injected animal. BRET imaging can also be performed with the unrestrained,
eleon expressing animal is placed under a two-photon laser scanning microscope,
cent Protein (CFP) using pulsed infrared laser light, CFP and Yellow Fluorescent Protein
ultiplier tubes. Upon nerve-electrode evoked muscle contraction, the increase in
-CFP emission ratio. The table below the drawings compares major features of the BRET
1322 T. Pozzan, R. Rudolf / Biochimica et Biophysica Acta 1787 (2009) 1317–1323including better BRET acceptors and higher sensitivity cameras for the
bioluminescence assay and fast, large ﬁeld microscopy with high
spatial resolution and low photodamage [163] for the ﬂuorescence
approach. Second, being able to just see mitochondrial Ca2+ dynamics
in a live, complex organism does not lead to the understanding of their
physiological meaning unless they can be correlated to further cellular
parameters under well-deﬁned experimental conditions. Apparently,
such parameters can be manifold, depending on the question of
interest. In the context of muscle physiology, these could be factors
like contractile kinetics and muscle force, mitochondrial membrane
potential and metabolic activity, pH, Ca2+ levels in cytosol and
sarcoplasmic reticulum, to name just a few. Actually, bioindicators are
available for some of these, but their implementation in combination
with mitochondrial Ca2+ measurement in vivo remains a major
challenge. However, our increasingly comprehensive understanding
of XFPs [164–166], is leading to a growing colour palette of ﬂuorescent
proteins [167–171]. Combined with recent advancements in the ﬁelds
of spectral unmixing of ﬂuorescent dye labels [172], multiple
ratiometric FRET imaging [173] and novel imaging techniques this
may soon allow for deeper insights into the signal–function relation-
ship of mitochondrial Ca2+ handling in live organisms.
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